clinical trial · NCT04638647
Secukinumab Open Label Roll-over Extension Protocol
Autoimmunity, InflammationSecukinumab s.c. injection
brief summary
The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment with secukinumab, and are unable to obtain the marketed secukinumab formulation.
started
Dec 22, 2020
primary completion
Jan 29, 2030
completion
Apr 4, 2030
last updated
Mar 11, 2026
official title
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol